SS-31

SS-31 is another name for elamipretide, a synthetic peptide that binds mitochondrial cardiolipin. The target is structurally specific, which distinguishes it from claims based only on nonspecific antioxidant activity^1,6.

FDA approval applies to the branded drug for a narrowly defined Barth-syndrome population under accelerated approval. It does not establish that this compounded preparation is equivalent or that healthy adults gain energy, endurance or longevity^5,6.

Development focused on mitochondrial dysfunction and cardiolipin-associated membrane biology. This led to clinical programs in several distinct diseases rather than a single established general-purpose mitochondrial therapy^1,5.

The FDA milestone followed an unusual evidence path involving a small randomized trial and a long open-label extension. Continued approval depends on confirmation of clinical benefit; the accelerated status belongs in the explanation of the evidence⁶.

Cardiolipin helps organize the inner mitochondrial membrane and respiratory machinery. Elamipretide localizes to that membrane and influences mitochondrial morphology and function^1,6.

Preclinical work links these changes to improved energy production and less oxidative injury in experimental settings. Mechanistic plausibility is not sufficient to predict fatigue or exercise outcomes across different diseases^1,2.

MMPOWER-3 randomized 218 people with primary mitochondrial myopathy. At 24 weeks it did not improve its primary walk-distance or fatigue endpoints relative to placebo; the between-group walk estimate was -3.2 m².

The Barth-syndrome crossover study randomized 12 participants and also missed its initial primary endpoints. Improvements appeared during the open-label extension, which cannot exclude expectation, training, natural variation or selection effects³.

The long-term extension reported a cumulative +96.1 m walk-distance change at 168 weeks, with 8 participants reaching that visit. FDA accelerated approval was based on knee-extensor muscle strength, not proof of general walking or wellness benefit^4,6.

Injection-site reactions were common in the clinical programs, and the approved label warns about serious hypersensitivity. Renal function affects exposure and clinical dosing decisions^2,4,6.

The label also addresses benzyl-alcohol toxicity in neonates for the branded formulation. A compounded vial may differ in excipients, concentration and storage, so its identity and handling must be assessed separately⁶.

FORZINITY is a ready-to-use subcutaneous liquid with brand-specific excipients and handling⁶. This catalog vial is a different compounded preparation; confirm whether it is lyophilized or liquid, its route and its own storage instructions rather than borrowing the brand’s.

The catalog specifies vial content, not a verified final formulation or storage specification. A lyophilized preparation requires the pharmacy-specified compatible diluent; a ready-to-use liquid does not. Follow the dispensing label for refrigeration, light protection and the beyond-use date, and use aseptic technique with a new sterile needle and syringe⁷. Dosing is set by your provider.